Imaging of bone tumors using a monoclonal antibody raised against human osteosarcoma

✍ Scribed by Nicholas C. Armitage; Alan C. Perkins; Malcolm V. Pimm; Martin Wastie; John S. Hopkins; Francis Dowling; Robert W. Baldwin; Jack D. Hardcastle

• Publisher: John Wiley and Sons
• Year: 1986
• Tongue: English
• Weight: 573 KB
• Volume: 58
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19860701)58:1<37::aid-cncr2820580108>3.0.co;2-4

✦ Synopsis

The radiolabeled monoclonal antibody 791T/36 raised against a human osteosarcoma was injected into 20 patients with known or suspected bone tumors. Gamma camera images were acquired at 48 or 72 hours after injection, and assessed for antibody localization. Positive images were obtained in all five osteosarcomas and four other primary malignant sarcomas. Two of the four other primary bone tumors gave positive images. Three patients with trauma had negative images as did one patient with Paget's disease. Two patients with suppurative disease gave positive images. The antibody localized in the majority of malignant sarcomas tested. In one tumor where tissue was available, a tumor:non-tumor ratio of 2.8:l was measured. Repeat imaging was performed in five patients. Immunoscintigraphy using the monoclonal antibody 791T/36 has shown tumor localization in patients with bone and soft tissue sarcomas.

Cancer 58:37-42, 1986.

STEOSARCOMA is the most common primary malig-0 nant bone tumor affecting young patients in particular. Combinations of surgery, radiotherapy, and chemotherapy have achieved some improvement in the outlook, but overall, about half of all patients still die of their tumor within 5 years.'.2

Technetium 99m-methylene diphosphonate ( 9 9 m T ~-MDP) bone imaging offers little advantage over skeletal radiographs in the imaging of primary osteogenic sarcomas,' although combined bone and Gallium scintigraphy appears to be a reliable predictor of malignancy in patients